Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:05 PM
Ignite Modification Date:
2025-12-24 @ 12:05 PM
NCT ID:
NCT00002061
Eligibility Criteria:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
* History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, and severe gastric ulcer.
* Lymphoid malignancy.
* Infectious mononucleosis caused by cytomegalovirus (CMV) or Epstein-Barr virus (EBV).
* Heart disease (especially if receiving cardiac glycosides).
* Hemophilia.
Patients with the following are excluded:
* Kaposi's sarcoma or overt opportunistic infections.
* Active evidence of infectious mononucleosis caused by Epstein-Barr virus (EBV) or cytomegalovirus (CMV) as determined by heterophile test (EBV) or cell culture (CMV).
* A history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, and severe gastric ulcer.
* Critical illness.
* Condition requiring hospitalization.
* Women of childbearing age are excluded.
Prior Medication:
Excluded:
* Steroids, cytotoxic immunosuppressive agents.
* Antiviral medicine.
* Excluded within 1 month of study entry:
* Immunomodulators (including Isoprinosine).
Prior Treatment:
Excluded:
* Radiotherapy.
Patients who have unexplained immunodepression and are at risk of developing AIDS.
* Patients with prolonged generalized lymphadenopathy for 3 or more months (greater than 1 cm at two or more noncontiguous sites).
IV drug abuse.
Healthy Volunteers:
False
Sex:
MALE
Minimum Age:
18 Years
Maximum Age:
50 Years
Study:
NCT00002061
Study Brief:
Protocol Section:
NCT00002061